A Phase 2 interventional study of CABAZITAXEL (XRP6258) and DOCETAXEL (XRP6976) in Prostatic Neoplasms, sponsored by Sanofi. Completed at 8 sites in Brazil. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-24.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing cabazitaxel in Prostatic Neoplasms — 6 open to participants now, 10 under way, none of them phase 3. cabazitaxel · Prostatic Neoplasms.
Among the 46 studies testing cabazitaxel in Prostatic Neoplasms, this one is the 41st largest by enrollment, is one of 6 that started in 2012, is one of 28 in phase 2, and was the 11th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →6 of the 46 studies testing cabazitaxel in Prostatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:
Case Comprehensive Cancer Center · Sites in United States
Ages 19+
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
Fundacion Oncosur · Sites in Spain
Ages 18+ · Men only
Jina Pharmaceuticals Inc.
Ages 18+ · Men only
By country, each count listing its studies:
cabazitaxel: first FDA approval 2010 (JEVTANA KIT), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 32 · Phase 3 7 · Phase 4 2
First in 2007; this study’s year is marked. 6 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2 is below the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 60 across the 46 interventional studies. Of the 29 that completed or were terminated, 14 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 46 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
34 studies in Prostatic Neoplasms by Sanofi: none open now, none under way, none of them phase 3. Of 34 finished, 14 (41%) have results posted.
Among the 34 studies in Prostatic Neoplasms by Sanofi, this one is the 31st largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2012, is one of 14 in phase 2, and was the 27th registered.
Sanofi’s Prostatic Neoplasms studies by the year they started, since 2001.
2 of the studies testing cabazitaxel in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06890832Jina Pharmaceuticals Inc.A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer | 2026-12 |
| NCT06085729M.D. Anderson Cancer CenterPhase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) | 2027-09-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 46 studies testing cabazitaxel in Prostatic Neoplasms, from their registry updates:
Among Sanofi’s 34 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
Secondary Objectives:
Screening: 21days (+7 days) Treatment: until PSA progression Post-treatment Follow-up: 2 years
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
75 mg/m2, administered as a 1-hour intravenous infusion, every 3 weeks
Drug: DOCETAXEL (XRP6976)
25 mg/m2, administered as a 1-hour intravenous infusion, every 3 weeks
Drug: CABAZITAXEL (XRP6258)
Pharmaceutical form: solution Route of administration: intravenous
Pharmaceutical form: solution Route of administration: intravenous
Median time to PSA progression
Time frame: up to 60 days
PSA response rate: Percentage of patients with a decrease of at least 50% in the PSA
Time frame: up to 60 days
Overall Survival: Median time elapsed between the date of starting treatment until death by any cause
Time frame: up to a maximum of 2 years
Number of patients with adverse events
Time frame: up to a maximum of 2 years
The record gives a start of Aug 2012, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabazitaxel